Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor Corporation (NYSE: DXR) announced that President and CEO Michael Feldschuh will present at the 2021 Emerging Growth Virtual Conference on March 17-19, 2021. He will discuss Daxor's recent achievements, including revenue growth, research advancements, and new contracts with the US Department of Defense. The company's BVA-100® blood test aims to improve management in critical care, COVID-19, and heart failure. Investors can view the presentation online and request one-on-one meetings with Feldschuh afterward.
Daxor Corporation (NYSE: DXR) has secured a $750,000 phase-two contract from the USAF to enhance its blood volume measurement technology. This contract marks the fourth award from the DoD in two years, totaling over $2 million. The funding will facilitate the development of a new fluorescent tracer and optical sensing technology, expanding the capabilities of the BVA-100 Blood Volume Analyzer for both military and civilian applications. The innovative system aims to improve patient resuscitation and treatment outcomes.
Daxor Corporation (NYSE: DXR) reported a 50.4% revenue increase for its operating division in fiscal 2020, driven by strong sales and leasing of its blood volume analysis systems and military contracts from the US Department of Defense. The company’s NAV rose to $3.89, a 14% increase from $3.41 in 2019. Additionally, Daxor is advancing next-generation BVA technology with support from the NIH and ongoing clinical studies. The commercialization efforts led by new VP Jean Oertel aim to further expand market reach and enhance revenue growth in the coming year.
Daxor Corporation (NYSE: DXR) has received a grant from the Center for Advancing Point of Care Technologies to develop a smart heart failure diagnostic for intravascular fluid overload. This funding accelerates Daxor's R&D of next-generation devices for blood volume measurement, a critical need as heart failure affects over 6 million Americans annually. The point-of-care diagnostics market is projected to reach $46.7 billion by 2024, driven by a rising incidence of heart conditions and a shift towards home healthcare.
Daxor Corporation (NYSE: DXR) recently presented compelling findings at the Society for Critical Care Medicine's 50th Congress. A study conducted by the University of Hawaii revealed that the BVA-100 blood test effectively measures blood volume status post massive blood transfusions, outperforming traditional clinical metrics in 80% of cases analyzed. Only 20% of patients were found to be euvolemic, while 24% were hypovolemic despite normal clinical indicators. Daxor's BVA-100 test aims to enhance treatment precision, potentially improving patient outcomes in critical care settings.
Daxor Corporation (NYSE: DXR) announced its participation in the SCCM 50th Congress Virtual Event from January 31 to February 12, 2021, showcasing its BVA-100 blood test research from the University of Hawaii. The study indicates that BVA-100 can enhance patient care by significantly reducing mortality rates by 66% and altering SICU interventions in 44% of cases compared to standard methods. The company aims to improve healthcare outcomes through precise fluid management.
Daxor Corporation (NYSE: DXR) has entered into a distribution agreement with L1 Enterprises to promote its BVA-100 blood volume analysis test. This agreement targets federal healthcare agencies, including the Department of Defense and Veterans Affairs, to enhance patient care for conditions like heart failure and critical care.
CEO Michael Feldschuh emphasized the collaboration's potential to improve health outcomes for veterans, while L1 Enterprises highlighted the technology's role in reducing mortality rates and saving costs for the government.
Daxor Corporation (NYSE: DXR) announced that CEO Michael Feldschuh will present at the H.C. Wainwright BioConnect Investment Conference from January 11-14, 2021. He will discuss Daxor's innovative BVA-100® blood test, which has been used in over 50,000 assessments for various medical conditions, including heart failure. The company is also conducting a multi-center trial on COVID-19 and has contracts with the U.S. Department of Defense for advanced Blood Volume Analyzers.
FAQ
What is the current stock price of Daxor Corporation (DXR)?
What is the market cap of Daxor Corporation (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
